| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
Director
2 companies
Andreas Wicki last filed a Form 4 in December 2022, as Director at HRMY. The filings on record cover 2 companies. Andreas Wicki's net worth is not public. Form 4 filings only show shares in the companies where this person was an insider, as of the last filing.
Our model assigns Andreas Wicki a strong insider score of 71/100, based on 33 past trades. Over a 12-month horizon, 75.8% of those trades were profitable, with an average 12-month return of +20.0%.
At the last filing, the largest reported position was 2,147,943 shares of HRMY. The HRMY filings lean toward selling, a net 2,493,836 shares.
Andreas Wicki has 20 Form 4 filings on record from November 2018 to December 2022, across 2 companies: Director at Harmony Biosciences (HRMY), 2021–2022; Director at Pacira BioSciences (PCRX), 2018–2021.
The 49 reported transactions were 49 open-market sales.
Counted by filing, the open-market trades come to no purchases and 20 sales worth about $167.8M.
The largest open-market sale was 576,767 shares of HRMY at an average $59.09 on November 4, 2022, about $34.1M. Twelve months later HRMY was down 56%.
Shares as reported in the last Form 4 for each company; the most recent is from December 2022. Values use today's prices. Any trades after the last filing were not reported, so current holdings may differ.
| Date | Ticker | Role | Type | Shares | Price | Value | Chg% | 3M | 12M | SEC |
|---|---|---|---|---|---|---|---|---|---|---|
| Dec 14, 2022 | HRMY Harmony Biosciences Holdings, Inc. | Director | Sell | 28,841 | $60.31 | $1,739,342.36 | -1.3% | -29.2% | -42.4% | |
| Dec 5, 2022 | HRMY Harmony Biosciences Holdings, Inc. | Director | Sell | 77,853 | $61.23 | $4,766,939.19 | -3.5% | -28.9% | -46.8% | |
| Nov 15, 2022 | HRMY Harmony Biosciences Holdings, Inc. | Director | Sell | 51,278 | $59.31 | $3,041,490.80 | -2.2% | -16.3% | -55.1% | |
| Nov 10, 2022 | HRMY Harmony Biosciences Holdings, Inc. | Director | Sell | 129,408 | $58.89 | $7,620,541.30 | -5.3% | -16.8% | -59.5% | |
| Nov 4, 2022 | HRMY Harmony Biosciences Holdings, Inc. | Director | Sell | 576,767 | $59.09 | $34,079,776.10 | -19.1% | -17.0% | -56.0% | |
| Aug 10, 2022 | HRMY Harmony Biosciences Holdings, Inc. | Director | Sell | 578,552 | $53.77 | $31,106,469.22 | -16.1% | +11.8% | -38.9% | |
| Aug 5, 2022 | HRMY Harmony Biosciences Holdings, Inc. | Director | Sell | 72,586 | $52.73 | $3,827,163.14 | -2.0% | +14.2% | -36.0% | |
| Mar 11, 2022 | HRMY Harmony Biosciences Holdings, Inc. | Director | Sell | 285,587 | $45.24 | $12,919,670.40 | -7.2% | +6.2% | -5.9% | |
| Mar 3, 2022 | HRMY Harmony Biosciences Holdings, Inc. | Director | Sell | 596,428 | $40.62 | $24,227,112.28 | -13.1% | +2.8% | +3.8% | |
| Dec 10, 2021 | HRMY Harmony Biosciences Holdings, Inc. | Director | Sell | 27,268 | $40.09 | $1,093,148.27 | -0.6% | +19.7% | +54.8% |